In several cases, fluoxetine, its metabolites, its known artifacts, and supposedly tranylcypromine were detected in urine using the authors' systematic toxicological analysis (STA) procedure based on acid hydrolysis, extraction, and acetylation. As fluoxetine and tranylcypromine are absolutely contraindicated drugs and in none of the cases was tranylcypromine prescribed, the question of whether the detected compound might have been formed by fluoxetine and/or its metabolites arose. Therefore, rat urine taken after dosing with fluoxetine was screened in the same way. In addition, aqueous solutions of fluoxetine, norfluoxetine, tranylcypromine, and a mixture of the latter two drugs were worked-up and analyzed according to the STA and without hydrolysis. In urine specimens obtained from rats dosed with fluoxetine, tranylcypromine was detected as well as in the solution of worked-up norfluoxetine including hydrolysis. Its underlying mass spectrum could be identified by detailed interpretation of the fragmentation patterns as acetylated 3-phenyl-propyl-2-ene-amine. This compound could be postulated as hydrolysis product of norfluoxetine formed by ether cleavage and water elimination. Although this spectrum shows nearly the same fragmentation patterns as that of acetylated tranylcypromine, both compounds could finally be differentiated by their retention indices and by using the positive-ion chemical ionization mode.
Introduction
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is used as an antidepressant. It is mainly metabolized through N-demethylation by cytochrome P450 enzymes, especially CYP2D6, forming its active metabolite norfluoxetine (1) (2) (3) . Tranylcypromine is an irreversible inhibitor of the monamineoxidases A and B and contraindicated in combination with SSRIs because both drugs could lead to a serotonin syndrome (4) .
In urine drug screenings of psychiatric patients, fluoxetine, its metabolites, its known artifacts, and supposedly tranylcypromine were detected using the authors' systematic toxicological analysis (STA) procedure based on acid hydrolysis, extraction and acetylation (5, 6) . Because concomitant use of both drugs is contraindicated, tranylcypromine was not prescribed, and the patients showed no serotonin syndrome, the question of whether the detected compound might have been formed by fluoxetine and/or its metabolites arose. Therefore, the aim of this study was to elucidate a possible analytical pitfall.
Experimental

Materials, chemicals and reagents
Tranylcypromine was obtained from Roehm Pharma (Darmstadt, Germany), fluoxetine from Lilly Deutschland (Bad Homburg, Germany), norfluoxetine from Sigma (Taufkirchen, Germany), N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) from Fluka (Steinheim, Germany), and all other chemicals and reagents from Merck (Darmstadt, Germany). All were of analytical grade.
Human urine samples
Human urine samples were submitted from psychiatric hospitals to the authors' laboratory for clinical toxicological analysis.
Rat urine samples
Investigation of work-up artifacts of fluoxetine and/or its metabolites was performed using urine samples from male Wistar rats (Ch. River, Sulzfleck, Germany) for toxicological diagnostic reasons, according to the corresponding German law. They were administered a single 3.5 mg/kg body mass dose of fluoxetine in aqueous suspension by gastric intubation. Urine was collected separately from the feces over a 24-h period.
Blank urine samples were collected before drug administration to check whether the urine samples were free of interfering compounds.
Urine work-up
A 5-mL aliquot of human or rat urine was divided into two equal parts. One 2.5-mL portion was refluxed with 1 mL 37% hydrochloric acid for 15 min. Following hydrolysis, the sample was basified with 2 mL aqueous ammonium sulfate solution (30%) and 1.5 mL sodium hydroxide (10 mol/L) to obtain a pH between 8 and 9. Before extraction, the second 2.5 mL part of untreated urine was added. This solution was extracted with 5 mL extraction solvent mixture (ethyl acetate/dichloromethane/ 2-propanol, 3:1:1, v/v/v). The organic phase was evaporated to dryness (70°C, reduced pressure) and derivatized by acetylation, according to the literature (5,6). The residue was dissolved in 100 µL methanol, and 2 µL was injected into the gas chromatography-mass spectrometry (GC-MS) system.
Spiked water samples and work-up
To 2.5 mL water each, 100 µL methanolic solution of either tranylcypromine (1 mg/mL), fluoxetine (1 mg/mL), norfluoxetine (1 mg/mL), or a mixture of tranylcypromine and norfluoxetine were added. One set of the spiked samples was hydrolyzed as described earlier, and one set was left without acid hydrolysis. Both sets were extracted as described earlier. The residues were derivatized by acetylation (AC), trifluoroacetylation (TFA), and trimethylsilylation (TMS), and the aliquots were injected into the GC-MS according to the literature (5-7).
GC-MS analysis
All samples were analyzed using a Hewlett Packard (Agilent, Waldbronn, Germany) 5890 series II GC with an HP 5989B MS Engine MS and an HP MS ChemStation (DOS series) with HP G1034C software. The GC conditions were as follows: splitless injection mode, column, Varian (Darmstadt, Germany) factor FOUR VF-1ms capillary (12 m × 0.2-mm i.d.), cross-linked methyl silicone, 330-nm film thickness, injection port temperature, 280°C, carrier gas helium, flow rate 1 mL/min, column temperature programmed from 100 to 310°C at 30°C/min, initial time 3 min, final time 8 min. The MS conditions were as follows: full-scan mode, m/z 50-550 u; electron ionization (EI) mode: ionization energy 70 eV, chemical ionization using methane; and positive mode (PICI): ionization energy 230 eV, ion source temperature 220°C, capillary direct interface heated at 260°C.
Results and Discussion
Human urine sample
In several human urine samples, besides fluoxetine, its metabolites, and its known artifacts, tranylcypromine was supposedly detected using the authors' STA procedure based on acid hydrolysis, extraction, and acetylation. The EI mass spectrum of the compounds falsely detected as tranylcypromine is depicted in Figure 1A . Figure 1B shows the mass spectrum of acetylated tranylcypromine falsely matched by library search using the MPW_2007 library (8) . As fluoxetine and tranylcypromine are contraindicated drugs, and in none of the cases was tranylcypromine prescribed, the question of whether the detected compound might have been formed by fluoxetine and/or its metabolites arose. Therefore, rat urine taken after dosing with fluoxetine was screened in the same manner.
Rat urine sample
In the rat urine samples, worked-up according to the STA, the same EI mass spectrum ( Figure 1A ) was found besides those of fluoxetine and its main metabolite norfluoxetine. As tranylcypromine was not administered to the rat and the blank urine sample was drug-free, tranylcypromine itself or a similar compound might have been formed from fluoxetine and/or its metabolites.
Water samples spiked with tranylcypromine, fluoxetine, and/or norfluoxetine
In the unhydrolyzed samples, only the corresponding derivatized drugs could be detected. In the hydrolyzed samples, derivatized tranylcypromine and/or the known fluoxetine hydrolysis artifact and/or the compound, which EI mass spectrum of is depicted in Figure 1A , could be detected. As the mass spectrum was only detected in hydrolyzed samples containing norfluoxetine, the compound, so far supposed to be tranylcypromine, should be a hydrolysis artifact of norfluoxetine. Figure 2 shows the possible degradation pathway of norfluoxetine under acid hydrolysis conditions, that is, cleavage of the ether moiety followed by water elimination to 3-phenylpropyl- 2-eneamine (norfluoxetine artifact), which has the same molecular weight as tranylcypromine.
EI fragmentation of the acetylated norfluoxetine artifact and tranylcypromine
According to the EI mass spectra of the acetylated norfluoxetine artifact and acetylated tranylcypromine ( Figure 1A and 1B), the postulated fragmentation patterns are given in Figure 3 and can be explained as follows. Generally, two concomitant patterns could be observed. On the one hand, both compounds could undergo elimination of the acetyl moiety in form of the ketene CH 2 CO to the corresponding primary amines with the fragment ions of m/z 133. In the case of acetylated tranylcypromine, the following loss of a hydrogen radical should result in the opening of the cyclopropane ring at the β-position to the substituent leading to the base peak of m/z 132. This was already described by Belanger et al. (9) using high-resolution MS. This most abundant fragment might also be formed from the acetylated norfluoxetine artifact by a hydrogen radical loss. As a consequence of this common fragment, the subsequent fragmentation step, the loss of ammonia yielding a cyclic ion of m/z 115, should be identical for tranylcypromine and the norfluoxetine artifact. Furthermore, fragmentation of ion m/z 133 should occur for acetylated tranylcypromine as well as for the acetylated norfluoxetine artifact and should be as follows: expulsion of the phenyl radical should give a 4-membered cyclic ion with m/z 56, and ion radical m/z 116 should result from the loss of NH 3 . On the other hand, the acetylated compounds with m/z 175 might be fragmented as follows: benzylic cleavage to m/z 91 and side chain cleavage after relocation to the fragments m/z 84 and m/z 60. Regarding these postulated fragmentation patterns, it could be explained why both compounds produced nearly identical EI mass spectra. Both mass spectra only differentiated in the abundance of the molecular ions m/z 175 and the fragments m/z 60, which could be caused by the lower stability of acetylated tranylcypromine under EI conditions.
Differentiation of norfluoxetine artifact and tranylcypromine
The norfluoxetine artifact and tranylcypromine are isobaric compounds and show very similar EI mass spectra without and after acetylation, trifluoroacetylation, or trimethylsilylation (the corresponding mass spectra will be published elsewhere) (10) . As shown in Figure 1 , PICI allowed distinguishing between the acetylated norfluoxetine artifact and tranylcypromine via fragment m/z 134 formed by elimination of the acetyl moiety only of tranylcypromine.
As given in Figure 1 , both compounds could also be differentiated via their retention indices recorded during the GC-MS procedure and calculated in correlation with the Kovats' indices (11) of the components of a standard solution of typical drugs, which is measured daily for testing the GC-MS performance (12). However, considering the possible variation of ±50 units, both compounds could only be differentiated by co-chromatography after addition of acetylated tranylcypromine to the fluoxetine urine extract. Of course, these problems could be overcome by using gentle enzymatic cleavage of conjugates, which is, however, too time-consuming in emergency toxicology (13) .
Conclusions
The presented study showed that the simultaneous detection of fluoxetine, norfluoxetine, and supposed tranylcypromine in human urine samples may not be caused by comedication of two contraindicated drugs but by an analytical pitfall. The supposed tranylcypromine was shown to be a hydrolysis artifact of norfluoxetine. Knowledge of artifact formation of the drugs and their metabolites may help toxicologists avoid such pitfalls.
